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Background. The upper anterior abdominal wall is a very unusual location for an ectopic pregnancy making optimal management
uncertain. Case. We report the case of a 26-year-old gravida 4, para 1, aborta 2 with a rising quantitative human chorionic
gonadotropin level following a negative diagnostic laparoscopic examination. She was subsequently diagnosed with an abdominal
wall ectopic pregnancy 2cm inferior to the liver. A single percutaneous intralesional injection of methotrexate was successful
after initial failure with systemic methotrexate. Conclusion. Systemic methotrexate is a logical ﬁrst choice for management of a
stable early abdominal wall pregnancy. Direct intralesional injection of methotrexate as the next treatment choice may avoid the
morbidity linked with operative management.
Copyright © 2009 Paynesha M. Anderson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Abdominal ectopic pregnancies are extremely rare and
accountforonly1%ofallectopicpregnancies[1].Thegesta-
tional sac of an abdominal pregnancy usually implants in the
pelvisoronhighlyvascularareassuchastheliver,spleen,and
mesentery [1] and can be associated with excessive maternal
morbidity and mortality. The risk of maternal morbidity is
7-8 time greater with an abdominal ectopic pregnancy com-
pared with other ectopic pregnancy locations and 90 times
greater than an intrauterine pregnancy [2]. Given the rarity
of an abdominal ectopic pregnancy and the potential mor-
tality associated with abdominal pregnancies, early diagnosis
and appropriate clinical treatment is essential. We present a
unique case of failed systemic methotrexate therapy followed
by a successful intralesional methotrexate injection for treat-
ment of an infrahepatic abdominal wall ectopic pregnancy.
2. Patient History
A 26-year-old gravida 4, para 1, aborta 2 presented to an
outside facility reporting spotting and cramping with a
quantitative human chorionic gonadotropin (hCG) level
of 8,979mIU/mL. The patient was at 3 weeks and 2 days
gestation by a sure last menstrual period. The patient had
a Mirena IUD removed 2 days prior to her last menstrual
periodatherrequestbecauseshedesiredtobecomepregnant
again. The IUD at the time of removal was normally located.
An ultrasound noted an empty uterus with an endometrial
stripe of 7mm and a complex cystic lesion of the left ovary
which measured 6 × 3 × 5cm. The patient was released to
return the following day for a repeat quantitative hCG level
which increased to 9,564mIU/mL. She was then transferred
to another outside facility for surgical management of a
presumed ectopic pregnancy. Interval quantitative hCG
level rose to 15,638mIU/mL over the next 24 hours, and
a diagnostic laparoscopy was performed. The complex
appearing cystic left ovary was reported as benign in
appearance and left in situ. There was no evidence of ectopic
pregnancy observed. The upper abdomen was not reported
as having been examined in the operative report.
Two days later the patient was referred to Naval Medical
Center Portsmouth where she was admitted. Baseline serum2 Obstetrics and Gynecology International
laboratory values, tumor markers, and a repeat pelvic ultra-
sound were obtained. The ultrasound noted ﬂuid in the pos-
terior cul-de-sac, right ovary with a suspected corpus luteal
cyst, left ovary with a conglomerate of hemorrhagic cysts,
endometrial stripe of 3mm, and no intrauterine pregnancy.
Tumor markers were all normal, and the quantitative hCG
level was reported as 23,274mIU/mL. A D&C performed
on the date of admission revealed no evidence of products
of conception with a continued increasing quantitative hCG
level on the following day to 25,678mIU/mL.
A CT scan of the chest, abdomen, and pelvis was
per-formed to look for evidence of a possible hormone-
secreting tumor or abdominal pregnancy causing the ris-
ing quantitative hCG levels. Computed tomography (CT)
imaging of the abdomen revealed a 2.2cm complex cystic
structure 2cm inferior to the inferior hepatic border which
was suspicious for an ectopic abdominal gestational sac
(Figure 1). A localized abdominal ultrasound was performed
following the CT report; however, no speciﬁc ectopic could
be identiﬁed by ultrasound.
The patient was counseled on treatment options in-
cluding our recommendation of nonsurgical therapy with
methotrexate. The planned therapy was 2 doses of
methotrexate 50mg/m2 IM on day 0 and day 4 as described
by Barnhart to increase systemic methotrexate concentration
with minimal overall toxicity. The quantitative hCG level
on the day of treatment was 30,678mIU/mL with a follow
up quantitative hCG level on the fourth day following the
initial treatment of 47,285mIU/mL. Due to the 35% increase
in quantitative hCG level following the ﬁrst treatment, the
2-dose intramuscular plan was abandoned in favor of an
intralesional injection planned for Day 7 in coordination
with our Interventional Radiology Department given the
patient’s stable condition. The patient’s quantitative hCG
level slightly decreased to 44,637mIU/mL by Day 7 when a
formal ultrasound noted an ectopic abdominal pregnancy
inferior to the liver with a crown rump length (CRL)
consistent with an estimated gestational age of 7 weeks and 4
days. Fetal cardiac activity was demonstrated at 167 beats per
minute (Figure 2).
The Interventional Radiology service was consulted
and performed a direct injection of methotrexate into the
gestational sac. A draped 4MHz vector transducer with
needle guide was placed transabdominally in the right
upper quadrant to visualize the gestational sac. There was
documentedfetalcardiacactivitypriortotheprocedure.The
patient received conscious sedation with intravenous Versed
and Fentanyl. A 10cm, 20-gauge Chiba needle was then
advanced into the gestational sac and appeared to be within
the fetal pole (Figure 3). A total of 25mg (0.25mL) was
introduced into the gestational sac. Immediate postprocedu-
ral ultrasonography demonstrated persistent cardiac activity
of 156 beats per minute. There were no postprocedural
complications.
Anultrasoundexamination performedthenext morning
documented continued fetal cardiac activity without sig-
niﬁcant interval change of the gestational sac. On day 4
after the intralesional methotrexate injection (Day 11 from
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Figure 1: Computed tomography (CT) imaging of the abdomen
revealing a 2.2cm complex cystic structure 2cm inferior to the
inferior hepatic border which was suspicious for an ectopic
abdominal gestational sac.
Figure 2: Initial ultrasound image of infrahepatic region of the
abdominal wall noting a gestational sac with yolk sac and fetal pole.
the intramuscular injection of the ﬁrst dose of methotrex-
ate), the patient’s quantitative hCG level had decreased to
35,622mIU/mL. A repeat ultrasound examination at this
time revealed absence of fetal cardiac activity.
The patient was discharged from the hospital and seen in
follow up within 1 week. Her recovery following discharge
from the hospital was uneventful, and she was returned
to full activity by the third week after discharge. The only
sequela noted from treatment was musculoskeletal pain
at the site of injection. The patient’s quantitative hCG
levels were followed weekly until they were negative for 3
consecutive weeks. Fourteen weeks later the gestational sac
remainsclearlyvisiblebybedsideultrasound,thoughthesizeObstetrics and Gynecology International 3





Abdominal ectopic pregnancies are rare and account for
only 1% of all ectopic pregnancies [1]. Although these
pregnancies are infrequently encountered, the possibility of
an unusual location for an ectopic must always be part
of the practitioner’s diﬀerential diagnosis. It is extremely
importanttoconsistentlyperformafullvisualsurveyofboth
the pelvis and upper abdomen during laparoscopy when
evaluating for an ectopic pregnancy, especially if normal
pelvic anatomy is noted, and this does not correlate with the
observed quantitative hCG level. If clinical suspicion has not
beenconﬁrmedbyoperativeﬁndings, radiographic scanning
with CT or magnetic resonance imaging (MRI) may assist
in diagnosis. Risk factors for an ectopic pregnancy should
be considered additive and raise the index of suspicion with
each additional risk factor possessed by the patient. This
patient had a history of a Chlamydia infection and was also
using an IUD for contraception. With calculation of the CRL
of the fetus to date the gestational age of the pregnancy, we
discovered that the patient had actually conceived prior to
the removal of the IUD.
Although the diagnostic tools to identify an abdominal
pregnancy are well established, the optimal treatment is less
certain. To diagnose a primary abdominal pregnancy, the
criteria described by Studdiford should be met: (1) normal
tubes and ovaries, (2) no evidence of uteroperitoneal ﬁstula,
and (3) pregnancy related solely to the peritoneal surface
and no evidence of secondary implantation following initial
primary tubal nidation [1]. Because abdominal pregnancies
typicallyimplantonhighlyvascularsurfacessuchastheliver,
spleen, omentum, large blood vessels, or abdominal serosa,
the most minimally invasive but most eﬀective means of
treatment must be used.
Many diﬀerent agents have been used to treat ectopic
pregnancies including systemic and local methotrexate,
local potassium chloride and hyperosmolar glucose, prost-
aglandins, danazol, etoposide, and mifepristone [3]. Most
investigators have reported varying success rates in the
medical treatment of abdominal pregnancies with local
potassium chloride and/or local methotrexate, sometimes
with the addition of systemic methotrexate [4]. When local
treatment has failed, this has resulted in repeat dosing or
surgical removal. Local injection has several advantages over
systemic administration: increased local eﬀectiveness with
increased therapeutic levels of the drug at the site of the
ectopic, decreased number of treatment courses, decreased
systemic toxicity, and the ability to evaluate for the cessation
of fetal cardiac activity.
There have been no reported cases in literature of the
medical treatment of an abdominal ectopic implantation to
the less vascular anterior abdominal wall unassociated with
a prior low transverse abdominal wall scar. Given the close
proximity to such a highly vascular organ, we sought to ﬁnd
the most minimally invasive treatment for our patient. Few
casereportshaveobservedsuccesswithonlytheintralesional
injection of ectopic pregnancies in various locations such
as the cervix, fallopian tube, or liver parenchyma [5]
withouttheconcomitantuseofpotassiumchlorideinjection.
Successful intralesional injection of methotrexate alone in an
abdominal ectopic has only been reported in one case of an
intrahepatic ectopic [5]. In our case, we observed a Day-
4 increase of the quantitative hCG level by 35% following
systemic methotrexate and determined that this was a poor
prognosticfactorforaseconddoseofsystemicmethotrexate.
Our management was likely successful with a single dose of
intralesional methotrexate because of the early gestational
age. Avoidance of surgical removal of the ectopic lesion was
accomplished with no long term sequelae exhibited by the
patient. In the stable patient who fails systemic methotrexate
therapy, intralesional injection of an abdominal wall ectopic
pregnancy presents an eﬀective, minimally invasive treat-
ment option which should be attempted prior to surgical
removal.
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